CureVac N.V. (CVAC) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
CureVac N.V. (CVAC) Bundle
Looking to determine the intrinsic value of CureVac N.V.? Our CVAC DCF Calculator integrates real-world data with comprehensive customization features, enabling you to refine your forecasts and make more informed investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.2 | 51.0 | 107.4 | 70.3 | 56.0 | 76.4 | 104.1 | 141.9 | 193.4 | 263.6 |
| Revenue Growth, % | 0 | 180.78 | 110.61 | -34.54 | -20.26 | 36.3 | 36.3 | 36.3 | 36.3 | 36.3 |
| EBITDA | -95.4 | -128.3 | -402.9 | -218.3 | -244.0 | -76.4 | -104.1 | -141.9 | -193.4 | -263.6 |
| EBITDA, % | -525.38 | -251.73 | -375.27 | -310.57 | -435.45 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 5.0 | 14.2 | 37.4 | 27.3 | 24.4 | 26.3 | 35.9 | 48.9 | 66.7 | 90.8 |
| Depreciation, % | 27.34 | 27.83 | 34.84 | 38.8 | 43.5 | 34.46 | 34.46 | 34.46 | 34.46 | 34.46 |
| EBIT | -100.3 | -142.5 | -440.3 | -245.5 | -268.4 | -76.4 | -104.1 | -141.9 | -193.4 | -263.6 |
| EBIT, % | -552.72 | -279.56 | -410.1 | -349.37 | -478.95 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 33.5 | 1,381.4 | 850.7 | 521.5 | 422.3 | 76.4 | 104.1 | 141.9 | 193.4 | 263.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 17.9 | 1.9 | 56.0 | 9.4 | 41.2 | 36.9 | 50.2 | 68.5 | 93.3 | 127.2 |
| Account Receivables, % | 98.49 | 3.73 | 52.18 | 13.35 | 73.5 | 48.25 | 48.25 | 48.25 | 48.25 | 48.25 |
| Inventories | 6.5 | 15.1 | 58.5 | 25.0 | 25.9 | 30.8 | 42.0 | 57.2 | 78.0 | 106.3 |
| Inventories, % | 35.58 | 29.72 | 54.53 | 35.58 | 46.13 | 40.31 | 40.31 | 40.31 | 40.31 | 40.31 |
| Accounts Payable | 5.6 | 18.4 | 127.5 | 71.1 | 48.3 | 53.9 | 73.5 | 100.1 | 136.5 | 186.1 |
| Accounts Payable, % | 30.61 | 36.04 | 118.71 | 101.23 | 86.25 | 70.58 | 70.58 | 70.58 | 70.58 | 70.58 |
| Capital Expenditure | -12.7 | -49.4 | -133.3 | -97.2 | -57.5 | -71.3 | -97.2 | -132.5 | -180.6 | -246.2 |
| Capital Expenditure, % | -70.19 | -96.83 | -124.19 | -138.27 | -102.68 | -93.4 | -93.4 | -93.4 | -93.4 | -93.4 |
| Tax Rate, % | -0.07616293 | -0.07616293 | -0.07616293 | -0.07616293 | -0.07616293 | -0.07616293 | -0.07616293 | -0.07616293 | -0.07616293 | -0.07616293 |
| EBITAT | -100.1 | -141.7 | -439.4 | -245.4 | -268.6 | -76.2 | -103.9 | -141.6 | -193.0 | -263.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -126.7 | -156.8 | -523.8 | -291.5 | -357.2 | -116.3 | -170.2 | -232.0 | -316.3 | -431.1 |
| WACC, % | 16.14 | 16.14 | 16.14 | 16.14 | 16.14 | 16.14 | 16.14 | 16.14 | 16.14 | 16.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -752.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -440 | |||||||||
| Terminal Value | -3,110 | |||||||||
| Present Terminal Value | -1,472 | |||||||||
| Enterprise Value | -2,224 | |||||||||
| Net Debt | -376 | |||||||||
| Equity Value | -1,848 | |||||||||
| Diluted Shares Outstanding, MM | 221 | |||||||||
| Equity Value Per Share | -8.37 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: CureVac N.V.’s (CVAC) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Provides detailed unlevered and levered DCF valuation models tailored for CureVac N.V. (CVAC).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to CVAC.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to match CureVac's strategies.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to CureVac N.V. (CVAC).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Download the Template: Gain immediate access to the Excel-based CVAC DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically recalculates CureVac’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial decisions.
Why Choose This Calculator for CureVac N.V. (CVAC)?
- Designed for Experts: A sophisticated tool tailored for researchers, investors, and financial analysts.
- Comprehensive Data: CureVac’s historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience.
Who Should Use CureVac N.V. (CVAC)?
- Biotechnology Students: Explore cutting-edge mRNA technology and its applications in real-world scenarios.
- Researchers: Utilize CureVac's innovative models in your studies or clinical trials.
- Investors: Evaluate your investment strategies and analyze the market performance of CureVac N.V. (CVAC).
- Healthcare Analysts: Enhance your analysis with a tailored financial model specific to biotech firms.
- Pharmaceutical Entrepreneurs: Understand how established biotech companies like CureVac N.V. (CVAC) navigate the industry.
What the Template Contains
- Historical Data: Includes CureVac N.V.'s (CVAC) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate CureVac N.V.'s (CVAC) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of CureVac N.V.'s (CVAC) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.